Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Xarelto Vs Pradaxa"

13:45 EDT 24th July 2014 | BioPortfolio

Matching Channels

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Pradaxa, Xarelto, Eliquis: NOACs' Reversal a Key?

(MedPage Today) -- The new oral anticoagulants, or NOACs -- dabigatran (Pradaxa), rivaroxaban (Xarelto), and Eliquis (apixaban) -- are touted for their safety, efficacy, and ease of use, but they have...

Pradaxa Available in the UK for DVT, PE

Boehringer Ingelheim has announced that Pradaxa will be commercially available in the UK for the treatment of DVT and PE and the prevention of recurrent

Xarelto Lawsuit News: The Rottenstein Law Group Comments on New Study that Shows Xarelto® Surpassing Pradaxa in the Number of Reported Injuries

The firm currently represents patients who allege that they have suffered serious side effects from use of Xarelto. Rockville Centre, NY (PRWEB) June 26, 2014 The Rottenstein Law Group LLP, a nationa...

Can Eliquis Play Catch Up? New Indication Should Help

Pfizer and Bristol-Myers Squibb’s Eliquis is now approved for a new use after orthopedic surgery. In competition with the broadly labeled Xarelto and Boehringer’s Pradaxa, Eliquis had a slower tha...

Xarelto in long-term clot prevention study

Bayer has launched a trial of its anticoagulant Xarelto in long-term, secondary prevention of blood clots.The EINSTEIN CHOICE study will investigate Xarelto (rivaroxaban) 10 mg and 20 mg once daily fo...

Bayer Submits Xarelto for DVT, PE Approval in Japan

Bayer HealthCare’s oral anticoagulant Xarelto (rivaroxaban) has been submitted to the Japanese Ministry of Health, Labor and Welfare (MHLW) for marketing authorization to treat

Physician Views: Can Bayer deliver on its Xarelto bullishness?

Recently added to the BioPortfolio report store, Physician Views: Can Bayer deliver on its Xarelto bullishness? is a new report from Firstword published on 2014-03-09. This report is available from...

BI Kicks Off Pradaxa First Ablation Trial

Boehringer Ingelheim announced the initiation of a new international study of Pradaxa (dabigatran etexilate mesylate).

Matching PubMed Articles

Perioperative management and therapy of bleeding complications.

The new oral anticoagulants directly inhibit either thrombin (Dabigatran, Pradaxa®,) or activated Factor X (rivaroxaban, Xarelto®, and apixaban, Eliquis®) and have been approved for thromboprophyla...

Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice.

To explore and detail clinical experiences of dabigatran, a novel anticoagulant, after it became available in New Zealand in July 2011.

{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.

In October 2011, DTB reviewed the use of dabigatran, the first new oral anticoagulant licensed for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillatio...

Rivaroxaban: A Review of Its Use in the Treatment of Deep Vein Thrombosis or Pulmonary Embolism and the Prevention of Recurrent Venous Thromboembolism.

Rivaroxaban (Xarelto(®)), an oral direct factor Xa inhibitor, is approved for the initial treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the prevention of recurrent D...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement